C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018
This report can be delivered to the clients within 48 hours
'C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 20+ products along with 18+ companies involved. Dompe Farmaceutici, BioLineRx, and X4 Pharmaceuticals are among the developers of most promising pipeline products.
Products covered by Phase
Pipeline analysis of 20+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for C-X-C Chemokine Receptor (CXCR) Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
'C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 20+ products along with 18+ companies involved. Dompe Farmaceutici, BioLineRx, and X4 Pharmaceuticals are among the developers of most promising pipeline products.
Products covered by Phase
- Marketed Products
- Phase III, Phase II and Phase I
- Pre-clinical and Discovery
Pipeline analysis of 20+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for C-X-C Chemokine Receptor (CXCR) Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
- The report provides competitive pipeline landscape of C-X-C Chemokine Receptor (CXCR) Inhibitors
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for C-X-C Chemokine Receptor (CXCR) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the C-X-C Chemokine Receptor (CXCR) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for C-X-C Chemokine Receptor (CXCR) Inhibitors and also provide company profiling
- Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Establish a comprehensive understanding of the current pipeline scenario C-X-C Chemokine Receptor (CXCR) Inhibitors to formulate effective R&D strategies
- Assess challenges and opportunities that influence C-X-C Chemokine Receptor (CXCR) Inhibitors R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor (CXCR) Inhibitors pipeline depth and focus of target therapeutics
- Developing strategic initiatives to support your drug development activities
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for C-X-C Chemokine Receptor (CXCR) Inhibitors to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
- Gaining a full picture of the Competitive Landscape for Evidence based Decisions
Executive Summary
Overview
Introduction
Structure of CXC Receptors
Key CXCR Inhibitors as Drug Targets
CXCR4 Inhibitor
Mechanism of Action
CXCR4 in Different Indications
CXCR4 in Rheumatoid Arthritis
CXCR4 and WHIM syndrome
CXCR4 and Metabolic Disorders
Competitive Landscape – Active Products
Active Pipeline Coverage by Indication
Marketed and Pipeline Products
Marketed Products
Mozobil: Sanofi Genzyme
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Global Sales of Mozobil
Historical and Forecasted Global Sales (2015-2027)
Mozobil - Analyst Insights
CXCR Inhibitors Class Share Evolution
Pipeline Therapeutics (Active Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Reparixin: Dompe Farmaceutici
Product Description
Research and Development
Product Development Activities
Reparixin Forecasted Sales
Reparixin - Analyst Insights
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant & Discontinued Products
Comparative Analysis
Appendix
Overview
Introduction
Structure of CXC Receptors
Key CXCR Inhibitors as Drug Targets
CXCR4 Inhibitor
Mechanism of Action
CXCR4 in Different Indications
CXCR4 in Rheumatoid Arthritis
CXCR4 and WHIM syndrome
CXCR4 and Metabolic Disorders
Competitive Landscape – Active Products
Active Pipeline Coverage by Indication
Marketed and Pipeline Products
Marketed Products
Mozobil: Sanofi Genzyme
Product Description
Regulatory Milestones
Research and Development
Other Clinical Activities
Product Development Activities
Global Sales of Mozobil
Historical and Forecasted Global Sales (2015-2027)
Mozobil - Analyst Insights
CXCR Inhibitors Class Share Evolution
Pipeline Therapeutics (Active Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Reparixin: Dompe Farmaceutici
Product Description
Research and Development
Product Development Activities
Reparixin Forecasted Sales
Reparixin - Analyst Insights
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant & Discontinued Products
Comparative Analysis
Appendix
LIST OF TABLES
Table 1: Active Pipeline Coverage by Indication
Table 2: Marketed and Pipeline Products
Table 3: Mozobil Historical and Forecasted Global Sales (2015-2027)
Table 4: Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
Table 5: Late Stage Products (Phase III)
Table 6: Reparixin Forecasted Sales (2020-2027)
Table 7: BL-8040 Forecasted Sales (2020-2027)
Table 8: X4P-001 Forecasted Sales (2020-2027)
Table 9: Mid Stage Products (Phase II)
Table 10: Early Stage Products (Phase I)
Table 11: Pre-clinical and Discovery Stage Products
Table 12: Assessment by Route of Administration
Table 13: Assessment by Stage and Route of Administration
Table 14: Assessment by Molecule Type
Table 15: Assessment by Stage and Molecule Type
Table 16: Dormant Products
Table 17: Discontinued Products
Table 1: Active Pipeline Coverage by Indication
Table 2: Marketed and Pipeline Products
Table 3: Mozobil Historical and Forecasted Global Sales (2015-2027)
Table 4: Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
Table 5: Late Stage Products (Phase III)
Table 6: Reparixin Forecasted Sales (2020-2027)
Table 7: BL-8040 Forecasted Sales (2020-2027)
Table 8: X4P-001 Forecasted Sales (2020-2027)
Table 9: Mid Stage Products (Phase II)
Table 10: Early Stage Products (Phase I)
Table 11: Pre-clinical and Discovery Stage Products
Table 12: Assessment by Route of Administration
Table 13: Assessment by Stage and Route of Administration
Table 14: Assessment by Molecule Type
Table 15: Assessment by Stage and Molecule Type
Table 16: Dormant Products
Table 17: Discontinued Products
LIST OF FIGURES
Figure 1: Structure of CXCR Inhibitors
Figure 2: Crystal Structure of the CXCR1 and CXCR2
Figure 3: CXCL8 Gene Regulation and Signaling Cascades Downstream of CXCL8-mediated CXCR1/2 Activation
Figure 4: CXCR 1 and 2 Mechanism in in Inflammatory Diseases
Figure 5: Crystal Structure of the Chemokine Receptor CXCR4
Figure 6: CXCR4 Mechanism in Cancer
Figure 7: CXCR4 mechanism in HIV Infection
Figure 8: CXCR4 Mechanism in Rheumatoid Arthritis
Figure 9: CXCR4 Mechanism in Cancer
Figure 10: Marketed and Pipeline Products
Figure 11: Mozobil Historical and Forecasted Global Sales (2015-2027)
Figure 12: Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
Figure 13: Late Stage Products (Phase III)
Figure 14: Reparixin Forecasted Sales (2020-2027)
Figure 15: BL-8040 Forecasted Sales (2020-2027)
Figure 16: X4P-001 Forecasted Sales (2020-2027)
Figure 17: Mid Stage Products (Phase II)
Figure 18: Early Stage Products (Phase I)
Figure 19: Pre-clinical and Discovery Stage Products
Figure 20: Assessment by Route of Administration
Figure 21: Assessment by Stage and Route of Administration
Figure 22: Assessment by Molecule Type
Figure 23: Assessment by Stage and Molecule Type
Figure 24: Dormant & Discontinued Products
Figure 1: Structure of CXCR Inhibitors
Figure 2: Crystal Structure of the CXCR1 and CXCR2
Figure 3: CXCL8 Gene Regulation and Signaling Cascades Downstream of CXCL8-mediated CXCR1/2 Activation
Figure 4: CXCR 1 and 2 Mechanism in in Inflammatory Diseases
Figure 5: Crystal Structure of the Chemokine Receptor CXCR4
Figure 6: CXCR4 Mechanism in Cancer
Figure 7: CXCR4 mechanism in HIV Infection
Figure 8: CXCR4 Mechanism in Rheumatoid Arthritis
Figure 9: CXCR4 Mechanism in Cancer
Figure 10: Marketed and Pipeline Products
Figure 11: Mozobil Historical and Forecasted Global Sales (2015-2027)
Figure 12: Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
Figure 13: Late Stage Products (Phase III)
Figure 14: Reparixin Forecasted Sales (2020-2027)
Figure 15: BL-8040 Forecasted Sales (2020-2027)
Figure 16: X4P-001 Forecasted Sales (2020-2027)
Figure 17: Mid Stage Products (Phase II)
Figure 18: Early Stage Products (Phase I)
Figure 19: Pre-clinical and Discovery Stage Products
Figure 20: Assessment by Route of Administration
Figure 21: Assessment by Stage and Route of Administration
Figure 22: Assessment by Molecule Type
Figure 23: Assessment by Stage and Molecule Type
Figure 24: Dormant & Discontinued Products
